GeneDx Holdings Corp.
Case Overview
9 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/03/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: GeneDx Holdings Corp. |
| Court: | Court: District of Connecticut |
| Case Number: | Case Number: 3:26cv00880 |
| Class Period: | Class Period: 04/16/2025 - 05/04/2026 |
| Ticker: | Ticker: WGS |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The lawsuit alleges that (1) the Company may have misled investors about the importance of Fabric Genomics; (2) as a result, the Company's margins would suffer; (3) the company's average reimbursement rates were not as "durable" as previously disclosed; (4) as a result of the foregoing, the Company's gross margins would decline; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per share of $0.28, and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint. GeneDx revealed it had “lower-than-expected blended average reimbursement rate for exome and genome” and “softer-than-expected performance from [its] noncore business lines” including Fabric Genomics. The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, “primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.” On this news, the price of GeneDx shares declined by $33.42 per share, or approximately 50%, from $67.93 per share on May 4, 2026 to close at $34.51 on May 5, 2026.
On May 4, 2026, GeneDx released its first quarter 2026 financial results, revealing earnings per share of $0.28, and a $57.5 million loss from operations. The Company also lowered its 2026 revenue guidance by approximately $65 million at the midpoint. GeneDx revealed it had “lower-than-expected blended average reimbursement rate for exome and genome” and “softer-than-expected performance from [its] noncore business lines” including Fabric Genomics. The Company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit, “primarily due to a downward revision of forecasted cash flows driven by changes in commercial strategy and go-to-market execution, and lower revenue and profitability expectations.” On this news, the price of GeneDx shares declined by $33.42 per share, or approximately 50%, from $67.93 per share on May 4, 2026 to close at $34.51 on May 5, 2026.